ClinicalTrials.gg
RecruitingNCT06844474Updated Sep 8, 2026

A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

A Phase 2 interventional study of SHR-1826;Adebrelimab;SHR-8068;Bevacizumab in NSCLC, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label, multicenter Phase II clinical trial to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in patients with NSCLC.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form.
  2. performance score of 0-1.
  3. ≥ 3 months.
  4. Have at least one measurable tumor lesion per v1.1.
  5. Subjects with confirmed locally advanced or NSCLC.
  6. Good level of organ function.
  7. Provide archived or fresh tumor tissue for vendor test.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with active central nervous system or meningeal metastases;
  2. History of serious cardiovascular and cerebrovascular diseases;
  3. Subjects with a history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis;
  4. Severe infection within 4 weeks prior to the first dose;
  5. Ongoing or previous anti-tumor therapies within 4 weeks prior to the first dose of study drug;
  6. Subjects with uncontrolled tumor-related pain;
  7. Received >30 Gy of non-thoracic radical radiation therapy within 4 weeks prior to the first administration of study drug;
  8. Concomitant other ≤ 5 years prior to first dose of study drug;
  9. Unresolved toxicities from previous anti-tumor therapy to ≤ Grade 1 (based on v5.0);
  10. History of immunodeficiency, including a positive test;
  11. Per the investigator's judgment, there are any other circumstances that may increase the risk of participating in the study, interfere with the study results, or make participation in the study inappropriate.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Arm A

    SHR-1826 for injection in combination with Adebrelimab injection and SHR-8068 with or without Bevacizumab injection

    Drug: SHR-1826;Adebrelimab;SHR-8068;Bevacizumab

Interventions

  • DrugSHR-1826;Adebrelimab;SHR-8068;Bevacizumab

    Drug: Drug: SHR-1826 Administration by intravenous infusion for a cycle of 3 weeks. Drug: Adebrelimab Administration by intravenous infusion for a cycle of 3 weeks. Drug: SHR-8068 Administration by intravenous infusion for a cycle of 6 weeks. Drug: Bevacizumab Administration by intravenous infusion for a cycle of 3 weeks.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) /serious adverse events(SAEs)

    Time frame: approximately 2 years

  2. Overall response rate (ORR)

    Time frame: approximately to 2 years

Secondary outcomes

  1. Duration of response (DoR)

    Time frame: approximately to 2 years

  2. Disease control rate (DCR)

    Time frame: approximately to 2 years

  3. Progression-free survival (PFS)

    Time frame: approximately to 2 years

  4. Overall survival (OS)

    Time frame: approximately to 5 years after last subject enrolled

07

Study locations

1 of 1 sites recruiting
  • Chinese People's Liberation Army (PLA) General Hospital
    Beijing, Beijing Municipality 100039, China
    Recruiting
    • Yi Hu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Mar 7, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06844474
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Mar 7, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

Li Song
Contact
li.song@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion